TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12969534
Drug: Accelerated fractionated
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerated fractionated radiotherapy with concurrent chemotherapy (AFC group, n=139, 6 fractions per week, 180‐190 cGy per day, total dose 7,400‐7,600 cGy, cisplatin and 5‐FU one time per week)
Study: 12969534
Drug: Conventional fractionated
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional fractionated radiotherapy (CF group, n=139, 5 fractions per week, 200 cGy per day, total dose 7,000‐7,600 cGy)
Study: 8944932
Drug: Peritoneal dialysis
Normalized name: Peritoneal dialysis solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peritoneal dialysis dose (KprT/V) ranging from 1.5 to 2.3
Study: 1683559
Drug: 800 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 micrograms ropinirole preceded by 20 mg domperidone
Study: 9051708
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg domperidone
Study: 1683559
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg domperidone followed by ropinirole-placebo
Study: 31475296
Drug: Sacubitril-valsartan (target
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sacubitril-valsartan (target dosage, 97/103 mg twice daily)
Study: 31475296
Drug: Enalapril (target
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (target dosage, 10 mg twice daily)
Study: 25752834
Drug: Rituximab treatment
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab treatment (single infusion)
Study: 23339809
Drug: Dual antiplatelet
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual antiplatelet therapy (DAPT) adherence within the first month
Study: 23339809
Drug: Dual antiplatelet
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual antiplatelet therapy (DAPT) adherence during 1-6 months
Study: 23339809
Drug: Dual antiplatelet
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual antiplatelet therapy (DAPT) adherence during 6-12 months
Study: 23339809
Drug: Dual antiplatelet
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual antiplatelet therapy (DAPT) adherence beyond one year
Study: 19919396
Drug: Bupropion (BUP)
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupropion (BUP) 150-300 mg
Study: 19919396
Drug: Bupropion combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupropion combined with transdermal nicotine (BUP+TN)
Study: 19919396
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (C) - no drugs
Study: 16890574
Drug: Ritonavir (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritonavir (300 mg twice daily for 2 days)
Study: 15310632
Drug: iv fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: iv fentanyl 2 to 3 microg.kg(‐1), propofol 2 mg.kg(‐1), and rocuronium 0.3 to 0.5 mg.kg(‐1)
Study: 11742191
Drug: Budesonide (6,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide (6, 9, or 18 mg daily)
Study: 11742191
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (steroid pretreatment)
Study: 8052507
Drug: 60 mg/kgbw
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg/kgbw Biltricide (Group 1)
Study: 8052507
Drug: 40 mg/kgbw
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg/kgbw (Group 2) - 12 Biltricide, 10 Distocide
Study: 1778089
Drug: Carbaryl lotion
Normalized name: carbaryl Topical Lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbaryl lotion
Study: 3148130
Drug: Malathion solution
Normalized name: Malathion
DrugBank: Malathion (DB00772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Malathion solution
Study: 3148130
Drug: Pyrethroid spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyrethroid spray
Study: 31037611
Drug: Chiglitazar 8
Normalized name: Chiglitazar
DrugBank: Chiglitazar (DB19023)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chiglitazar 8 mg
Study: 31037611
Drug: Chiglitazar 16
Normalized name: Chiglitazar
DrugBank: Chiglitazar (DB19023)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chiglitazar 16 mg
Study: 31037611
Drug: Chiglitazar 32
Normalized name: Chiglitazar
DrugBank: Chiglitazar (DB19023)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chiglitazar 32 mg
Study: 31037611
Drug: Chiglitazar 24
Normalized name: Chiglitazar
DrugBank: Chiglitazar (DB19023)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chiglitazar 24 mg
Study: 31037611
Drug: Chiglitazar 48
Normalized name: Chiglitazar
DrugBank: Chiglitazar (DB19023)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chiglitazar 48 mg
Study: 31037611
Drug: Chiglitazar 72
Normalized name: Chiglitazar
DrugBank: Chiglitazar (DB19023)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chiglitazar 72 mg
Study: 31037611
Drug: Chiglitazar 16
Normalized name: Chiglitazar
DrugBank: Chiglitazar (DB19023)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chiglitazar 16 mg (multiple doses)
Study: 21691610
Drug: Non-platform-switched implants
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-platform-switched implants
Study: 21691610
Drug: Implant platform
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implant platform 4.3 mm
Study: 21691610
Drug: Implant platform
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implant platform 4.8 mm
Study: 21691610
Drug: Implant platform
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implant platform 5.5 mm
Study: 17585313
Drug: pegaptanib sodium
Normalized name: Pegaptanib Sodium
DrugBank: Pegaptanib (DB04895)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: pegaptanib sodium (0.3, 1, and 3 mg)
Study: 9185468
Drug: Preoperative 50
Normalized name: ENSURE SURGERY PERIOPERATIVE KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative 50 mg flurbiprofen with standardized general anesthesia
Study: 9185468
Drug: Conventional combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional combined epidural and general anesthesia with epidural administration of 0.25% bupivacaine 5‐8 ml and 0.1‐0.2 mg buprenorphine after surgery
Study: 12766861
Drug: Flunarizine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunarizine (10 mg daily)
Study: 29722747
Drug: Cyclic natural
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclic natural progesterone therapy
Study: 27942208
Drug: Nebulized ipratropium
Normalized name: Ipratropium
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nebulized ipratropium bromide (500 µg)/salbutamol (2.5 mg)
Study: 24297940
Drug: High-dose cytarabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cytarabine (3,000 mg/m2 every 12 hours by 3-hour infusion on days 1, 3, 5, and 7)
Study: 24297940
Drug: Standard-dose cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Standard-dose cytarabine (100 mg/m2 per day by continuous infusion for 10 days)
Study: 21395141
Drug: Citrate anticoagulation
Normalized name: ANTICOAGULANT CITRATE DEXTROSE
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Citrate anticoagulation with 0.2% Prismocitrate 10/2 solution
Study: 17478491
Drug: L-carnitine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine (2 g i.v.) for 4 months
Study: 17478491
Drug: Placebo (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (2 g i.v.) for 4 months
Study: 17478491
Drug: Placebo (first
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (first 4 months) followed by L-carnitine (2 g i.v.) for 4 months
Study: 17478491
Drug: L-carnitine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine (0.5 mM and 5 mM) pre-incubation before agonist stimulation
Study: 10550151
Drug: High-dose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose chemotherapy with ifosfamide 10 g/m², carboplatin 1200 mg/m², and etoposide 1200 mg/m² (ICE)
Study: 10550151
Drug: High-dose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose chemotherapy with ifosfamide, carboplatin, and etoposide (ICE)
Study: 17825689
Drug: Titration group:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Titration group: 1 tablet of tramadol/acetaminophen 37.5/325 mg QD and 1 placebo BID for 3 days, followed by 1 active tablet BID and 1 placebo QD for 4 days, followed by 1 active tablet TID for 7 days.
Study: 17825689
Drug: Nontitration group:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nontitration group: 1 tablet of combined tramadol 37.5 mg/acetaminophen 325 mg TID for 14 days.
Study: 11176729
Drug: High-dose lisinopril
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose lisinopril (35.0 or 32.5 mg OD)
Study: 11176729
Drug: Low-dose lisinopril
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose lisinopril (5.0 or 2.5 mg OD)
Study: 11176729
Drug: Low-dose lisinopril
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose lisinopril
Study: 11176729
Drug: High-dose strategy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose strategy
Study: 9506648
Drug: Historical control
Normalized name: typhus, historical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Historical control (no treatment)
Study: 8155435
Drug: i.v. ketoprofen
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. ketoprofen 200 mg followed by 12.5 mg h‐1 over 13 h
Study: 8155435
Drug: extradural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: extradural morphine 4 mg
Study: 3247565
Drug: Local injections
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local injections of purified botulinum toxin type 'A'
Study: 3247565
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution injected with the same method as botulinum toxin
Study: 29698447
Drug: Celecoxib (absent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib (absent aspirin)
Study: 20521975
Drug: Red ginseng
Normalized name: Red ginseng
DrugBank: Ginseng (DB01404)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red ginseng extract powder (1 g) administered orally per week for 3 years
Study: 20521975
Drug: Red ginseng
Normalized name: Red ginseng
DrugBank: Ginseng (DB01404)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red ginseng extract powder (1 g) administered orally per week for 3 years (male subgroup)
Study: 17229323
Drug: 0 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 g alcohol (control)
Study: 8942463
Drug: D-cycloserine at
Normalized name: D-(+)-cycloserine
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-cycloserine at 50 mg/day
Study: 1653594
Drug: Lisinopril 20
Normalized name: lisinopril 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril 20 mg, increased to 80 mg if needed after 4 weeks
Study: 1653594
Drug: Atenolol 50
Normalized name: atenolol 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol 50 mg, increased to 200 mg if needed after 4 weeks
Study: 6354603
Drug: Antibiotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic treatment plus nimesulide (100 mg twice daily)
Study: 6354603
Drug: Antibiotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic treatment plus placebo
Study: 20961784
Drug: Pre-antiretroviral therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-antiretroviral therapy
Study: 17326029
Drug: Waterless alcohol-chlorhexidine
Normalized name: chlorhexidine / isopropyl alcohol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Waterless alcohol-chlorhexidine lotion
Study: 16303295
Drug: salbutamol 600
Normalized name: Salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: salbutamol 600 microg (6 x 100 microg via metered-dose inhaler)
Study: 11218985
Drug: 40 U
Normalized name: lipase 10440 UNT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 U of intranasal elcatonin (ELC) 2 months ON, 1 month OFF
Study: 6384285
Drug: Selenium sulfide
Normalized name: Selenium Sulfide
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Selenium sulfide (2.5%) lotion applied daily for 10 minutes for 7 consecutive days
Study: 27329037
Drug: 70g dark
Normalized name: dark leaved mugwort pollen extract
DrugBank: Artemisia ludoviciana pollen (DB10762)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 70g dark chocolate (150 mg epicatechin) with placebo capsules
Study: 27329037
Drug: Pure epicatechin
Normalized name: epicatechin
DrugBank: Epicatechin (DB12039)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pure epicatechin capsules (2 × 50 mg epicatechin) with 75g white chocolate
Study: 27329037
Drug: Placebo capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules with 75g white chocolate (0 mg epicatechin)
Study: 22607938
Drug: Topical ophthalmic
Normalized name: MIOTICS,TOPICAL OPHTHALMIC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical ophthalmic tofacitinib 0.005% QD
Study: 22607938
Drug: Topical ophthalmic
Normalized name: MIOTICS,TOPICAL OPHTHALMIC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical ophthalmic tofacitinib 0.003% BID
Study: 17031690
Drug: Low-dose cytarabine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose cytarabine and IFN-alpha
Study: 6749189
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of both agents
Study: 7733022
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg fluoxetine/d
Study: 6128740
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg lorazepam orally 1 hour before induction of labour
Study: 6128740
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no pre-induction medication)
Study: 31850844
Drug: Methylphenidate (catecholamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate (catecholamine transporter blocker)
Study: 11996469
Drug: Oxaliplatin 85
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxaliplatin 85 mg/m2 on day 1 and topotecan 1.5 mg/m2 on days 2-5
Study: 11996469
Drug: Oxaliplatin 85
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxaliplatin 85 mg/m2 on day 1 and topotecan 1.25 mg/m2 on days 2-5
Study: 11996469
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of oxaliplatin and topotecan
Study: 11996469
Drug: Oxaliplatin 85
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxaliplatin 85 mg/m2 and topotecan 1.25 mg/m2
Study: 24858755
Drug: Scaling and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scaling and root planing (SRP) followed by placement of Atridox gel (10% doxycycline hyclate)
Study: 19628729
Drug: levodopa/carbidopa (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: levodopa/carbidopa (100 mg/25 mg bid)
Study: 19628729
Drug: rotigotine (initial
Approvals — FDA: no, EMA: no, PMDA: no
Description: rotigotine (initial dose 2 mg/24 h for 3 days, followed by 4 mg/24 h)
Study: 19628729
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of levodopa/carbidopa and rotigotine
Study: 15134155
Drug: FertilityBlend (nutritional
Approvals — FDA: no, EMA: no, PMDA: no
Description: FertilityBlend (nutritional supplement)
Study: 10518174
Drug: Sertraline +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline + Group Cognitive Behavior Therapy
Study: 10518174
Drug: Group Cognitive
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group Cognitive Behavior Therapy
Study: 7758060
Drug: Granisetron 1
Normalized name: granisetron 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granisetron 1 mg BID
Study: 7758060
Drug: Granisetron 2
Normalized name: granisetron 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granisetron 2 mg BID
Study: 448576
Drug: Indomethacin (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (0.25 mg/kg)
Study: 448576
Drug: Indomethacin (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (0.3 mg/kg)
Study: 7924757
Drug: Indomethacin (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (all doses)
Study: 27881011
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy combined with bevacizumab intraperitoneal (i.p.)
Study: 27881011
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy combined with bevacizumab intravenous (i.v.)
Study: 22628120
Drug: Amoxycillin clavulanate
Normalized name: amoxicillin / clavulanate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxycillin clavulanate (22.5 mg/kg/dose, twice daily for 2 weeks)
Study: 17887949
Drug: 200 mg/day
Normalized name: alpelisib 200 mg/day (200 mg x 1) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg/day silymarin
Study: 12231521
Drug: Low-dose IL-2
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose IL-2 (1 x 10(6) IU/m(2)/day s.c. for 90 days)
Study: 12231521
Drug: Low-dose IL-2
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose IL-2 with intermediate pulse doses (6-12 x 10(6) IU/m(2)/day s.c. for 3 days every 14 days, maximum five pulses)
Study: 12231521
Drug: Low-dose IL-2
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose IL-2 with or without intermediate pulse dose therapy
Study: 12231521
Drug: Low-dose IL-2
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose IL-2 with intermediate pulse doses
Study: 9824783
Drug: Ganciclovir 1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ganciclovir 1,000 mg six times a day
Study: 9824783
Drug: Ganciclovir 1,500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ganciclovir 1,500 mg four times a day
Study: 9824783
Drug: Ganciclovir 2,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ganciclovir 2,000 mg three times a day
Study: 2789919
Drug: Timolol 20
Normalized name: timolol 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timolol 20 mg (positive control)
Study: 22860014
Drug: Dual blockade
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual blockade with enalapril (20 mg o.d.) and candesartan (16 mg o.d.)
Study: 22860014
Drug: Monotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy with enalapril or candesartan
Study: 3177010
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg bromocriptine
Study: 18093337
Drug: Cognitive-behavior therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavior therapy (CBT) alone
Study: 25931327
Drug: Nutritional supplements
Normalized name: nutritional supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional supplements alone
Study: 16227417
Drug: Spa resort
Normalized name: Broda Acne Spa
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spa resort treatment
Study: 10458255
Drug: Multilevel treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multilevel treatment algorithm based on the Agency for Health Care Policy and Research Guidelines for Cancer Pain Management
Study: 10458255
Drug: Standard‐practice pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard‐practice pain and symptom management therapies
Study: 7842187
Drug: Oral prednisolone
Normalized name: prednisolone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisolone (mean 10.1 mg daily)
Study: 7842187
Drug: Oral prednisolone
Normalized name: prednisolone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisolone (15 mg daily for 7 days)
Study: 7842187
Drug: Inhaled beclomethasone
Normalized name: beclomethasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled beclomethasone (500 micrograms twice daily for 7 days)
Study: 7842187
Drug: Control subjects
Normalized name: Ex vivo, lentiviral vector (LV)-mediated, genetically modified autologous cell therapy intended for the stable provision of functional human iduronate-2-sulfatase (IDS) enzyme to subjects with Hunter syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control subjects (not taking oral steroids)
Study: 2145871
Drug: UK 69,578
Approvals — FDA: no, EMA: no, PMDA: no
Description: UK 69,578 (10 mg/kg)
Study: 2145871
Drug: UK 69,578
Approvals — FDA: no, EMA: no, PMDA: no
Description: UK 69,578 (0.025 to 10.0 mg/kg)
Study: 28869786
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg dose of lorazepam
Study: 28869786
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg dose of lorazepam
Study: 28869786
Drug: 0.3 mg
Normalized name: biotin 0.3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg dose of lorazepam
Study: 28869786
Drug: 1.2 mg
Normalized name: RNA 1.2 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.2 mg dose of lorazepam
Study: 21062137
Drug: Aliskiren/valsartan 300/320
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aliskiren/valsartan 300/320 mg
Study: 15986954
Drug: Prompt L‐Pop
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prompt L‐Pop + SureFil with flowable resin composite
Study: 12682621
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose losartan (100 mg/day)
Study: 10726921
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg vanadyl sulfate (VOSO4)
Study: 10726921
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg vanadyl sulfate (VOSO4)
Study: 10726921
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg and 300 mg vanadyl sulfate (VOSO4)